Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.
Singh, S Carnaghi, C Buzzoni, R Pommier, R Raderer, M Tomasek, J Lahner, H Valle, Juan W Bubuteishvili-Pacaud, L Lincy, J
Singh, S
Carnaghi, C
Buzzoni, R
Pommier, R
Raderer, M
Tomasek, J
Lahner, H
Valle, Juan W
Bubuteishvili-Pacaud, L
Lincy, J
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial. 2016, 34(4) J Clin Oncol